PBE - Invesco Dynamic Biotechnology & Genome ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
48.48
-0.77 (-1.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close49.25
Open48.86
Bid0.00 x 800
Ask0.00 x 800
Day's Range48.48 - 49.00
52 Week Range43.17 - 60.49
Volume3,573
Avg. Volume20,572
Net Assets248.03M
NAV49.90
PE Ratio (TTM)N/A
Yield0.00%
YTD Return5.52%
Beta (3Y Monthly)1.43
Expense Ratio (net)0.59%
Inception Date2005-06-23
Trade prices are not sourced from all markets
  • Top and Flop ETFs So Far in Q2
    Zacks10 days ago

    Top and Flop ETFs So Far in Q2

    The top ETF stories so far this second quarter linger around upbeat U.S. economic data points and the U.S.-China trade talks.

  • Global X Launches GNOM ETF to Tap Booming Genomics Space
    Zackslast month

    Global X Launches GNOM ETF to Tap Booming Genomics Space

    Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.

  • Biotech ETFs Jump on Roche-Spark Deal
    Zacks3 months ago

    Biotech ETFs Jump on Roche-Spark Deal

    The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

  • ETF Trends3 months ago

    Spark Therapeutics Acquisition Sparks Rally in Biotechnology ETFs

    Biotechnology stocks and sector-specific ETFs climbed Monday after Roche (RHHBY) acquired gene therapy researcher Spark Therapeutics (ONCE). Among the best performing ETFs of Monday, the Invesco Dynamic ...

  • A Financial Overview of Sangamo Therapeutics in December 2018
    Market Realist5 months ago

    A Financial Overview of Sangamo Therapeutics in December 2018

    Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Revenue trends In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.

  • 7 Biotech ETFs to Consider for 2019
    InvestorPlace6 months ago

    7 Biotech ETFs to Consider for 2019

  • Amgen: Analysts’ Recommendations on October 25
    Market Realist7 months ago

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter—compared to revenues of $5.773 billion during the third quarter of 2017. The EPS is estimated to be $3.45 for the third quarter—compared to the EPS of $3.27 for the third quarter of 2017.

  • Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
    Market Realist7 months ago

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Biogen (BIIB), a leading biotechnology company, released its third-quarter earnings on October 23. Biogen surpassed Wall Street analysts’ estimates for EPS and revenues during the quarter. Biogen reported non-GAAP diluted EPS of $7.40 on revenues of ~$3.44 billion.

  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist7 months ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist9 months ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist9 months ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • Analysts Have Mixed Opinions about Ionis
    Market Realist9 months ago

    Analysts Have Mixed Opinions about Ionis

    What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.

  • ETF Trends10 months ago

    Biotech ETFs Rally as Illumina Tops Q2 Expectations

    Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best performing ETFs of Tuesday, the Invesco Dynamic Biotech & Genome (PBE) increased 3.0%, ARK Genomic Revolution Multi-Sector ETF (ARKG) advanced 2.5% and iShares Nasdaq Biotechnology ETF (IBB) rose 2.0%. Evercore analyst Ross Muken said in that the Illumina stock story is "far too compelling to ignore," reports Allison Gatlin for Investor's Business Daily.

  • Ionis Pharmaceuticals’ Valuation on May 23
    Market Realistlast year

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.